Funding
HEART
Open Access funding provided by the IReL Consortium. The SYNTAX Extended Survival study was supported by the German Foundation of Heart Research (Frankfurt am Main, Germany). The SYNTAX trial, during 0–5-year follow-up, was funded by Boston Scientific Corporation (Marlborough, MA, USA). Both sponsors had no role in the study design, data collection, data analyses, and interpretation of the study data, nor were involved in the decision to publish the final manuscript. The principal investigators and authors had complete scientific freedom. Science Foundation Ireland (Research Professorship Grant 15/RP/2765) grant to Dr William Wijns supports Drs R. Wang, M. Lunardi and C. Gao.